Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hemophilia: later-stage trial registry
3 of 10 indexed Hemophilia trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 3 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Hemophilia: 10 US clinical trials tracked, 3 recruiting.
Hemophilia is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Genzyme, a Sanofi Company, running 2 of these trials.
Enrollment posture brief
Registry condition hemophilia
OPEN 3 | RECR 30% | LATE 4 | EARLY 2 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adrenocortical Carcinoma (30% recruiting · 10 trials)
Hemophilia lists 3 open slots (30% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hemophilia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hemophilia is recruiting below its size-band peers.
3 of 10 indexed trials (30%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hemophilia research.
Genzyme, a Sanofi Company accounts for 2 of 10 trials (20%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Hemophilia trials plan to enrol fewer than 100 people.
Median target enrolment is 72 among the 10 trials that report a genuine target (sentinel values excluded). 8 of those (80%) plan for fewer than 100 participants.
-
Hemophilia research is mostly interventional.
8 interventional and 2 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
American Thrombosis and Hemostasis Network
NCT04398628
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Sanofi
NCT07285460
Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study
University of Minnesota
NCT06345833
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
Genzyme, a Sanofi Company
NCT03754790
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
Sanofi
NCT05662319
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
Genzyme, a Sanofi Company
NCT03974113
Clinical Trial of Factor XIII (FXIII) Concentrate
Children's Hospital of Orange County
NCT00640289
Motor Proficiency of People With Bleeding Disorders Using the BOT-2 (TM)
Oregon Health and Science University
NCT02279199
Treatment of Hepatitis C in Hemophilic Patients With HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00055341
The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders
Mary M. Gooley Hemophilia Center
NCT00697385
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Hemophilia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hemophilia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hemophilia page
10 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Hemophilia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Genzyme, a Sanofi Company sponsors the most Hemophilia trials on record, review their full trial history before evaluating a specific study. See Genzyme, a Sanofi Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hemophilia condition card totals 10 registered trials; most-linked intervention Fitusiran; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.